Press Releases

Date	Summary	View
Toggle SummaryNov 13, 2019	RedHill Biopharma to Host Third Quarter 2019 Financial Results Conference Call on November 19, 2019 TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...	View HTML PDF Version
Toggle SummaryNov 12, 2019	RedHill Biopharma Announces Publication of RHB-102 Gastroenteritis Phase 3 Study Results in JAMA TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...	View HTML PDF Version
Toggle SummaryNov 04, 2019	RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults RedHill plans to launch Talicia ® 1 in the U.S. in Q1/2020 for the treatment of H. pylori infection in adults, targeting more than two million patients estimated to be treated for H. pylori infection annually Talicia ® is the first and only FDA approved rifabutin-based H. ...	View HTML PDF Version
Toggle SummaryOct 29, 2019	RedHill Biopharma to Present at the BIO-Europe 2019 Conference TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 29, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...	View HTML PDF Version
Toggle SummaryOct 28, 2019	RedHill Biopharma to Present New Phase 3 Data on RHB-105 and RHB-104 at the American College of Gastroenterology 2019 Annual Meeting TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...	View HTML PDF Version
Toggle SummaryOct 18, 2019	RedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers’ Diarrhea Drug AEMCOLO TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...	View HTML PDF Version
Toggle SummaryOct 16, 2019	RedHill Biopharma Sponsors No Stomach For Cancer’s Symposium Ahead of Stomach Cancer Awareness Month TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 16, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...	View HTML PDF Version
Toggle SummaryOct 11, 2019	RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...	View HTML PDF Version
Toggle SummarySep 26, 2019	RedHill Biopharma Provides H2/2019 R&D Update TEL-AVIV, Israel and RALEIGH, N.C. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...	View HTML PDF Version
Toggle SummaryAug 27, 2019	RedHill Biopharma to Present at Upcoming Investor Conferences in September TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 27, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...	View HTML PDF Version

Subscribe to press releases